Please fill in all predictors to get an estimate of expected vancomycin exposure.
* = exposure estimates at steady state. ** = Probabilities of AUC24 > 400 and Ctrough > 20 mg/L at steady state.
If serum creatinine is not available for the neonate patient, consider using typical levels given below (Jaffé assay), but apply dosing tool with caution. Checking a serum creatinine is recommended.
|PMA (weeks)||Typical creatinine|
|24 − 28||1.2 mg/dL|
|29 − 34||0.8 mg/dL|
|35 − 41||0.6 mg/dL|
|≥ 42||0.4 mg/dL|
This web application was developed in collaboration between InsightRX and Adam Frymoyer, MD (Stanford University - Stanford Children's Health). It provides vancomycin starting dose advice for neonates based on a population pharmacokinetic model developed by Frymoyer A et al., described in AAC 2014 Nov; 58(11) with external validation described in Infect Dis Ther. 2015 Jun;4(2)
A description of the general tool framework can be found in Frymoyer A et al. J Pediatric Infect Dis Soc. 2017 (In Press). Please contact firstname.lastname@example.org for questions about the NeoVanco dosing tool.
This tool is intended for use in neonates with post-menstrual age <52 weeks, NO major congenital heart disease (other than VSD, ASD, PDA), and NO congenital kidney disease.
The dosing tool should not be used in patients on ECMO or renal replacement therapy. Caution is warranted in neonates with poor or worsening kidney function.
Disclaimer: This web application is provided the calculator is provided 'as is', without warranty of any kind, express or implied, including but not limited to the warranties of merchantability, fitness for a particular purpose and noninfringement. In no event shall the authors or copyright holders be liable for any claim, damages or other liability, whether in an action of contract, tort or otherwise, arising from, out of or in connection with this web application or the use or other dealings in the web application.
© InsightRX 2017, all rights reserved.